Most teams adopting AI in pharma run into the same early stumble: they treat every system as if it sits inside GxP, or they treat none of them as if they do. Both shortcuts cost money. The first over-scopes validation onto auxiliary tools that never touch product quality or patient safety. The second quietly attaches a model to a release-critical decision without the controls regulators expect. The useful question is narrower than “is AI compliant?” — it is “which specific use of this model falls under GxP, and what does that imply for validation, change control, and post-deployment monitoring?” The answer reshapes how a pharma organisation invests in AI across manufacturing, clinical trials, and the supply chain. What does GxP actually require when the software is AI? GxP is not a single regulation. It is a family — GMP for manufacturing, GCP for clinical trials, GLP for laboratory work, GDP for distribution — anchored to the same principle: any computerised system that influences a regulated decision must be qualified, validated, and kept under change control. In the EU, Annex 11 governs computerised systems in GMP; in the US, 21 CFR Part 11 governs electronic records and signatures. Both predate modern machine learning, and both still apply. What changes with AI is not the regulatory intent. It is the artefact being validated. A deterministic batch-record system has a fixed specification; you test it against that specification, lock the configuration, and re-test after any change. A trained model has weights derived from data, behaviour that shifts when retrained, and an output distribution that can drift as inputs evolve. ISPE’s GAMP 5 second edition and its companion AI guidance treat this by extending the existing GAMP categories — most production models land in Category 5 (custom application) — and adding lifecycle expectations around training data integrity, model versioning, and ongoing performance monitoring. Three operational implications follow: Validation evidence must cover the training set, not just the inference code. Provenance, labelling protocol, and any sampling bias become part of the qualified configuration. Change control extends to retraining. A weight update is a system change. It needs an impact assessment, a re-validation plan proportional to the change, and an entry in the audit trail. Post-deployment monitoring is not optional. The validated state is a snapshot; drift is the failure mode. Continuous performance checks, with predefined thresholds and an escalation path, are part of staying compliant. Where is the GxP boundary inside a pharma workflow? This is the question that determines how much validation work a team actually owes. The answer is not “AI is in scope” or “AI is out of scope” — it is “this specific use of this specific model produces a record or decision that GxP cares about.” AI use case GxP scope Why Visual inspection that pass/fails a vial for release In scope (GMP, Annex 1) Output is a quality decision on a released batch Cleanroom contamination monitoring tied to batch disposition In scope (GMP, Annex 1) Output feeds environmental monitoring records Protocol deviation prediction in a clinical trial In scope (GCP, ICH E6(R3)) Decisions affect trial conduct and subject data Demand forecasting for procurement Out of scope No direct influence on product quality or trial data Marketing sentiment analysis on social channels Out of scope No regulated decision Pharmacovigilance signal triage from social media In scope (GVP) Feeds adverse-event handling obligations Internal knowledge search across SOPs Borderline Depends on whether output is used to make a GxP decision without human review The borderline cases are where most disputes happen. A retrieval-augmented assistant that helps a QA reviewer find the right SOP is usually out of scope; the same assistant generating a deviation classification that is auto-routed without review is firmly in scope. The boundary is set by the decision the output drives, not by the technology underneath. This is exactly the scoping decision that GAMP 5’s risk-based approach is designed for. Validation effort should scale with the patient-safety and data-integrity risk of the AI’s role, not with the perceived novelty of the algorithm. How is a validated AI system kept compliant as the model drifts? The hard part of AI under GxP is not the initial qualification. It is the steady state. A model that passed acceptance testing in February may behave differently in August because the input distribution shifted — new suppliers, new packaging, a new patient cohort. The validated state has not changed on paper, but the system’s effective behaviour has. The mechanism regulators expect is straightforward in concept and demanding in practice: Define monitored properties. Pick the model behaviours that matter for the GxP decision — false-reject rate, sensitivity to a defect class, calibration of a risk score — and set acceptance thresholds based on the validation evidence. Instrument the production system. Log inputs, outputs, model version, and the downstream decision. Persist these in an audit-trail-compatible store so they survive inspection. Trigger investigation on threshold breach. A drift signal is a deviation. It enters the quality system, gets a CAPA if needed, and either resolves to a no-change conclusion or to a controlled retrain. Treat retraining as a change. New weights mean a new validated configuration. The depth of re-validation scales with the change — a fine-tune on the same data distribution is lighter than a re-train on a new defect class. In our experience across regulated-AI engagements, the failure pattern is almost never the initial validation package. It is the gap between deployment and the first drift signal, where nobody has agreed who owns the monitoring or what the threshold means. That is an observed pattern in our practice, not a benchmarked rate, but it shows up consistently enough that we treat the monitoring plan as a release-blocker, not a post-go-live item. Roles and documentation GAMP 5 assigns clear roles — system owner, process owner, QA, validation lead — and the AI case does not invent new ones. It does, however, redistribute the work. The data science team typically owns model performance and drift monitoring. QA owns the validated state and the change-control decision when the model is retrained. The system owner owns the integration with the GxP process and the link between model output and regulated record. ISPE’s AI maturity model is useful here mainly as a self-assessment lens — it helps teams see which of these handoffs they have actually formalised, versus which still live in informal Slack threads. Documentation discipline matters more with AI than with deterministic software because the artefact is harder to inspect. A reviewer can read code; they cannot read weights. The compensating evidence is data lineage, training protocol, performance characterisation across the input space, and a clear statement of intended use that bounds where the model is allowed to operate. Why scope discipline pays back Teams that map their AI portfolio onto the GxP boundary before building tend to spend less on validation, not more. The work concentrates on the systems that genuinely sit in scope, where deep evidence is unavoidable. The auxiliary systems — internal search, marketing analytics, supplier risk dashboards — run under normal IT controls without the GxP overhead. The release-critical systems get the validation depth they actually need, including the monitoring plan that makes the validated state durable. The opposite pattern — uniform “everything is GxP” treatment — is what stalls AI adoption in pharma. It is also what leads to brittle compliance, because effort spread thinly across every system rarely produces the depth a real GxP inspection demands. For the broader frame on how this fits into pharma regulatory operations, see our overview on AI in Life Sciences and the companion piece on continuous validation for AI-driven pharma compliance. FAQ What does GxP compliance specifically require when the software is AI/ML rather than deterministic code? The same intent — qualified, validated, change-controlled — applied to a different artefact. The validation package must cover training data integrity, model versioning, and ongoing performance monitoring, not just the inference code. GAMP 5’s second edition and ISPE’s AI guidance extend the existing categories rather than replacing them; most production models land in Category 5. Which GxP rules apply to AI training data, models, and inference outputs? Training data falls under data-integrity expectations (ALCOA+) — provenance, labelling protocol, and any selection bias must be documented. The model itself is treated as a controlled configuration item, with version control and an impact assessment for any retrain. Inference outputs are records under Annex 11 / 21 CFR Part 11 when they feed a regulated decision, which means audit trails, electronic signatures where applicable, and access controls. How is a GxP-validated AI system kept compliant as the model retrains or drifts? Through a monitoring plan defined at validation time, not bolted on afterwards. The plan specifies which model behaviours are monitored, the thresholds that trigger investigation, and the change-control path for retraining. A drift signal is treated as a deviation; a retrain is treated as a system change with re-validation scoped to the impact. Where is the boundary between GxP and non-GxP usage of AI inside a pharma manufacturing workflow? At the decision the output drives. AI that produces or directly influences a record regulators care about — batch release, environmental monitoring, deviation classification — is in scope. AI used for forecasting, marketing, or internal knowledge support is generally out of scope, with borderline cases resolved by whether a human reviews the output before a regulated decision. Which GxP roles own AI-specific risks and how is that documented? The data science team typically owns model performance and drift monitoring; QA owns the validated state and change-control decisions; the system owner owns the integration with the GxP process. Documentation must make these handoffs explicit, particularly around who declares a drift signal a deviation and who authorises a retrain. How do ISPE’s GAMP AI guidance and the ISPE AI maturity model fit into an existing GxP programme? GAMP 5 second edition and its AI companion extend the existing risk-based validation framework — they do not replace it. The AI maturity model is most useful as a self-assessment tool to identify which lifecycle handoffs (data governance, model change control, drift monitoring) are formalised versus informal. It is a diagnostic, not a compliance standard. How TechnoLynx supports GxP-scoped AI work We work with pharma teams on the boundary problem first: mapping the AI portfolio onto the GxP scope question, then building the validation and monitoring evidence the in-scope systems actually need. Our engagements cover visual inspection for sterile manufacturing, deviation prediction in clinical trials, and cleanroom monitoring tied to batch disposition — the use cases where the GxP scope is unambiguous and the validation depth has to match. We bring engineering ownership to the parts that pharma organisations typically struggle to staff internally: model versioning under change control, drift monitoring with predefined thresholds, and the documentation chain that survives inspection. References FDA (2023) Q7 Good Manufacturing Practice Guidance for Active Pharmaceutical Ingredients. https://www.fda.gov/files/drugs/published/Q7-Good-Manufacturing-Practice-Guidance-for-Active-Pharmaceutical-Ingredients-Guidance-for-Industry.pdf NIST (2023) AI Risk Management Framework. https://www.nist.gov/itl/ai-risk-management-framework ISPE (2024) GAMP 5 Guide: A Risk-Based Approach to Compliant GxP Computerized Systems, second edition. Image credits: DC Studio, via Freepik.
